TY - JOUR
T1 - Salvage high-dose-rate interstitial brachytherapy for pelvic recurrent cervical carcinoma after hysterectomy
AU - Murakami, Naoya
AU - Kato, Tomoyasu
AU - Miyamoto, Yuichiro
AU - Nakamura, Satoshi
AU - Wakita, Akihisa
AU - Okamoto, Hiroyuki
AU - Tsuchida, Keisuke
AU - Kashihara, Tairo
AU - Kobayashi, Kazuma
AU - Harada, Ken
AU - Kitaguchi, Mayuka
AU - Sekii, Shuhei
AU - Takahashi, Kana
AU - Umezawa, Rei
AU - Inaba, Koji
AU - Ito, Yoshinori
AU - Igaki, Hiroshi
AU - Itami, Jun
N1 - Funding Information:
This study was partially supported by the Japan Agency for Medical Research and Development, AMED, the National Cancer Center Research and Development Fund (26-A-18 and 26-A-28), and JSPS KAKENHI Grant Number 15K19836.
PY - 2016
Y1 - 2016
N2 - Background: The aim of this study was to report the clinical results of salvage high-dose-rate interstitial brachytherapy (HDR-ISBT) for patients with cervical cancer with pelvic recurrence after hysterectomy. Patients and Methods: When there was no indication for total pelvic extenteration (TPE) and the tumor depth was more than 5 mm of invasion in the paracolpium, salvage HDR-ISBT was applied. Results: A total of 26 patients were included in this study. The median number of fractions and dose per fraction of HDR-ISBT were 5 (range=3-20 fractions) and 6 Gy (range=2.5-6 Gy), respectively. Three-year local control, progression-free survival, and overall survival were 51.1%, 34.4% and 57.1%, respectively. Combination of external-beam radiation therapy, clinical target volume D90 greater than 65 Gy, and dose per fraction greater than 5 Gy were associated with favorable local control. Conclusion: For patients with recurrent cervical cancer post hysterectomy who are not candidates for TPE, salvage HDR-ISBT is a possible curative treatment modality.
AB - Background: The aim of this study was to report the clinical results of salvage high-dose-rate interstitial brachytherapy (HDR-ISBT) for patients with cervical cancer with pelvic recurrence after hysterectomy. Patients and Methods: When there was no indication for total pelvic extenteration (TPE) and the tumor depth was more than 5 mm of invasion in the paracolpium, salvage HDR-ISBT was applied. Results: A total of 26 patients were included in this study. The median number of fractions and dose per fraction of HDR-ISBT were 5 (range=3-20 fractions) and 6 Gy (range=2.5-6 Gy), respectively. Three-year local control, progression-free survival, and overall survival were 51.1%, 34.4% and 57.1%, respectively. Combination of external-beam radiation therapy, clinical target volume D90 greater than 65 Gy, and dose per fraction greater than 5 Gy were associated with favorable local control. Conclusion: For patients with recurrent cervical cancer post hysterectomy who are not candidates for TPE, salvage HDR-ISBT is a possible curative treatment modality.
KW - High-dose-rate interstitial brachytherapy
KW - Post hysterectomy relapse
KW - Salvage interstitial brachytherapy
KW - Uterine cervical cancer
UR - http://www.scopus.com/inward/record.url?scp=84994505995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994505995&partnerID=8YFLogxK
M3 - Article
C2 - 27127151
AN - SCOPUS:84994505995
SN - 0250-7005
VL - 36
SP - 2413
EP - 2421
JO - Anticancer Research
JF - Anticancer Research
IS - 5
ER -
